UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA ophthalmology, ISSN 2168-6165, 07/2020, Volume 138, Issue 7, pp. 747 - 748
Journal Article
JAMA ophthalmology, ISSN 2168-6165, 07/2019, Volume 137, Issue 7, pp. 745 - 746
Journal Article
Investigative ophthalmology & visual science, ISSN 0146-0404, 06/2020, Volume 61, Issue 6, pp. 27 - 27
Journal Article
JAMA ophthalmology, ISSN 2168-6165, 05/2018, Volume 136, Issue 8, pp. 884 - 885
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 03/2017, Volume 124, Issue 3, p. e33
Journal Article
JAMA ophthalmology, ISSN 2168-6165, 12/2016, Volume 135, Issue 2, pp. 114 - 115
Journal Article
7.
Full Text
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2012, Volume 119, Issue 7, pp. 1388 - 1398
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 13, pp. 1260 - 1261
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Diabetic Retinopathy - drug therapy | Visual Acuity - drug effects | Antibodies, Monoclonal, Humanized - administration & dosage | Humans | Macular Edema - drug therapy | Ranibizumab | Female | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Recombinant Fusion Proteins - administration & dosage | Bevacizumab | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Dropsy | Edema | Diabetics | Care and treatment | Analysis | Outcome and process assessment (Health Care) | Health aspects | Risk factors | Eye | Drugs | Diabetic retinopathy | Diabetes mellitus | Vision | Clinical trials | Retina | Diabetes | Drug therapy | Vascular endothelial growth factor | Eyes & eyesight | Index Medicus | Abridged Index Medicus
Journal Article
Movement disorders, ISSN 0885-3185, 09/2020, Volume 35, Issue 9, pp. 1542 - 1549
visual impairment | epidemiology | outcomes research | Parkinson’s disease | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Eye | Medical research | Medical examination | Medicare | Depression, Mental | Medicine, Experimental | Epidemiology | Health aspects | Risk factors | Dementia | Parkinson's disease | Neurodegenerative diseases | Mental disorders | Parkinsons disease | Mental depression | Hip | Fractures | Visual impairment | Anxieties | Dementia disorders | Anxiety | Movement disorders | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 1, pp. 122 - 129
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Male | Treatment Outcome | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Wet Macular Degeneration - drug therapy | Time Factors | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Aged | Visual Acuity - physiology | Cohort Studies | Fluorescein Angiography | Macular degeneration | Physiological aspects | Medical colleges | Angiogenesis inhibitors | Consulting services | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 9, pp. 1860 - 1870
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Follow-Up Studies | Macular Degeneration - physiopathology | Tomography, Optical Coherence | Humans | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Bevacizumab | Ranibizumab | Subretinal Fluid | Angiogenesis Inhibitors - therapeutic use | Visual Acuity - physiology | Fluorescein Angiography | Macula Lutea - pathology | Macular degeneration | Clinical trials | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Retina (Philadelphia, Pa.), 01/2021
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 3, pp. 593 - 599
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Bevacizumab | Ranibizumab | Serine Endopeptidases - genetics | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Complement C3 - genetics | Visual Acuity - physiology | Fluorescein Angiography | Pharmacogenetics | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Gene Frequency | High-Temperature Requirement A Serine Peptidase 1 | Genotype | Proteins - genetics | Macular Degeneration - genetics | Aged | Polymorphism, Single Nucleotide | Complement Factor H - genetics | Macular degeneration | Genes | Physiological aspects | Clinical trials | Genetic aspects | Angiogenesis inhibitors | Comparative analysis | Single nucleotide polymorphisms | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2015, Volume 122, Issue 4, pp. 809 - 816
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Geographic Atrophy - genetics | Intravitreal Injections | Humans | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Wet Macular Degeneration - genetics | Bevacizumab | Ranibizumab | Serine Endopeptidases - genetics | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Toll-Like Receptor 3 - genetics | Complement C3 - genetics | Visual Acuity - physiology | Fluorescein Angiography | Antibodies, Monoclonal, Humanized - therapeutic use | High-Temperature Requirement A Serine Peptidase 1 | Photography | Proteins - genetics | Wet Macular Degeneration - diagnosis | Geographic Atrophy - pathology | Wet Macular Degeneration - drug therapy | Aged | Polymorphism, Single Nucleotide | Complement Factor H - genetics | Cohort Studies | Macular degeneration | Growth | Physiological aspects | Clinical trials | Comparative analysis | Drug therapy | Vascular endothelial growth factor | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2014, Volume 121, Issue 1, pp. 150 - 161
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Follow-Up Studies | Geographic Atrophy - diagnosis | Humans | Middle Aged | Geographic Atrophy - drug therapy | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Genotyping Techniques | Bevacizumab | Incidence | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Geographic Atrophy - epidemiology | Wet Macular Degeneration - epidemiology | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Proportional Hazards Models | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Aged | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Risk factors | Biomedical engineering | Medical research | Medicine, Experimental | Index Medicus
Journal Article